TORNTPHARM · NSE
Torrent Pharmaceuticals Limited
₹4,689.5
+1.70% (+₹78.5)
Prev. close
₹4,611
Volume
2,00,042
Delivery %
61.1%
As of
20 Nov 2026
Price history
Analyst sentiment
Analysts are split
2 analyst stances · last 90 days · one per analyst
Trackable
2 · 1 bull / 0 neutral / 1 bear
Long-Horizon
none in range
Commentary
none in range
Trackable = verdict-bearing calls · Long-Horizon = 1yr+ horizon, verdict pending · Commentary = context, not graded
Analyst opinions
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Bearish on Torrent Pharma, recommending a sell at CMP ₹4,767 for a target of ₹4,250, with a stop loss at ₹5,050. The RSI…” | ET Bureau AnalysisET Bureau | Torrent Pharma | PENDING | |
| “Bullish on Torrent Pharma, recommending a buy at ₹4,965 with a stop loss at ₹4,700 and a target of ₹5,450, implying up t…” | Sachin GuptaChoice Equity Broking | Torrent Pharma | MISS | |
| “Bullish on Torrent Pharmaceuticals, which is in a strong uptrend across all time frames, well-placed above its key SMAs …” | Rajesh PalviyaAxis Securities | Torrent Pharmaceuticals Ltd | HIT | |
| “Bullish on Torrent Pharmaceuticals Ltd, recommending a buy between ₹3,780–3,810 with a target price of ₹4,050 in two to …” | Marketsmith India AnalysisMarketsmith India | Torrent Pharmaceuticals Ltd | HIT | |
| “Medium-term traders are advised to buy Torrent Pharma, targeting ₹4,400 in the next 3-4 months. This call follows the st…” | ETMarkets AnalysisETMarkets.com | Torrent Pharmaceuticals Ltd | HIT | |
| “Bullish on Torrent Pharmaceuticals Ltd, recommending a buy at ₹3,561.00 with a stop loss at ₹3,543.00 and a target price…” | Ankush BajajIndependent | Torrent Pharmaceuticals Ltd | HIT | |
| “Bullish on Torrent Pharmaceuticals, recommending a buy with a target price of ₹3,825 and a stop loss at ₹3,485. The stoc…” | Chandan TapariaMotilal Oswal Financial Services Ltd | Torrent Pharmaceuticals Ltd | HIT | |
| “Recommends accumulating Torrent Pharmaceuticals with a target price of ₹4,000. The call implies a bullish outlook on the…” | Prabhudas Lilladher AnalysisPrabhudas Lilladher | Torrent Pharmaceuticals | HIT | |
| “Bullish on Torrent Pharmaceuticals Ltd, recommending a buy around ₹3622.9 with a stop-loss at ₹3496 and a target of ₹387…” | Sumeet BagadiaChoice Equity Broking | Torrent Pharmaceuticals Ltd | HIT | |
| “Bullish on Torrent Pharma, which has broken out above a falling trendline and surpassed its previous swing high, confirm…” | Kunal KambleBonanza Portfolio | Torrent Pharmaceuticals Ltd | HIT | |
| “Bullish on Torrent Pharmaceuticals, recommending a buy around ₹3605 with a stop loss at ₹3480 for a target price of ₹388…” | Sumeet BagadiaChoice Equity Broking | Torrent Pharmaceuticals Ltd. | HIT | |
| “Suggests a Bull Call Ladder strategy for Torrent Pharma, which has broken out from a falling trendline and retested the …” | Choice Institutional Equities AnalysisChoice Institutional Equities | Torrent Pharmaceuticals Ltd | HIT | |
| “Short-term traders with a high-risk profile are advised to buy Torrent Pharma stock for a target of ₹3,600 within the ne…” | ETMarkets AnalysisETMarkets.com | Torrent Pharmaceuticals Ltd | HIT | |
| “Bullish on Torrent Pharma, recommending a buy at ₹3,375 with a target of ₹3,600 and a stop-loss at ₹3,250. The stock has…” | Rupak DeLKP Securities | Torrent Pharmaceuticals Ltd | HIT | |
| “Bullish on Torrent Pharma Ltd with a target of Rs 3650 and a stop loss at Rs 3230 for a short-term trading horizon.” | Rajesh PalviyaAxis Securities | Torrent Pharmaceuticals Ltd | MISS | |
| “Recommends buying Torrent Pharma with a target of ₹3,365 and a stop loss at ₹3,200, indicating a bullish outlook for sho…” | Jatin GediaSharekhan by BNP Paribas | Torrent Pharmaceuticals Ltd | MISS | |
| “Recommends accumulating Torrent Pharmaceuticals with a target price of ₹3,750. The call implies a bullish outlook on the…” | Prabhudas Lilladher AnalysisPrabhudas Lilladher | Torrent Pharmaceuticals | HIT | |
| “Recommends accumulating Torrent Pharmaceuticals with a target price of ₹3,600. The call implies a bullish outlook on the…” | Prabhudas Lilladher AnalysisPrabhudas Lilladher | Torrent Pharmaceuticals | PENDING | |
| “Recommends buying Torrent Pharma with a target price of ₹3600 and a stop loss at ₹3375. The call was made on October 27.” | Ganesh DongreAnand Rathi | Torrent Pharmaceuticals Ltd | MISS |
Market commentary · 5 · levels, conditionals, previews, macro & hedged views — context, not graded
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Bullish on Torrent Pharmaceuticals, recommending buying and accumulating the stock. It shows a continuation of the prior…” | Rajesh PalviyaAxis Securities | Torrent Pharmaceuticals Ltd | — | |
| “Bullish on Torrent Pharma in the longer term, as the acquisition of JB Chemicals, though expensive, will strengthen its …” | Amnish AggarwalPrabhudas Lilladher Capital | Torrent Pharmaceuticals Ltd | — | |
| “JPMorgan has upgraded Torrent Pharma to 'overweight', anticipating an 18% upside in the stock. This upgrade led to a 4% …” | JPMorgan AnalysisJPMorgan | Torrent Pharmaceuticals Ltd | — | |
| “Maintains a 'Hold' call on Torrent Pharmaceuticals with a 12-month target price of Rs 3,320. The rationale includes expe…” | JM Financial AnalysisJM Financial Institutional Securities | Torrent Pharmaceuticals Ltd | — | |
| “Jefferies recommends buying Torrent Pharmaceuticals, projecting a potential upside of 22-28% over the next 12 months. De…” | Jefferies AnalysisJefferies | Torrent Pharmaceuticals | — |
Fundamentals
About Torrent Pharmaceuticals Limited
Torrent Pharmaceuticals Limited engages in the research, development, manufacturing, marketing, and distribution of branded and generic pharmaceutical formulations in India, the United States, Brazil, Germany, Malta, and internationally. The company offers products in various therapeutic areas, including anti-diabetic, anti-microbial, cardiovascular, CNS, urology, gynecology, oncology, gastro-intestinal, nephrology, neuro-psychiatric, dermatology, pulmonology, pediatric treatments, nutritional, pain management, anti-infective, and miscellaneous, as well as vitamins, minerals, and nutrients. It also provides contract manufacturing services. The company offers its products under Tedibar, Shelcal, Unienzyme, ProZuca, and Ahaglow brands. The company was formerly known as Trinity Laboratories and changed its name to Torrent Pharmaceuticals Limited in 1971. The company was founded in 1959 and is based in Ahmedabad, India. Torrent Pharmaceuticals Limited is a subsidiary of Torrent Investments Private Limited.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Sanjay Gupta
Headquarters
Ahmedabad
Employees
18,258
Website
torrentpharma.comExchange
View on NSE ↗Key stats
Market cap
₹1.79 L Cr
P/E ratio (TTM)
79.4
Dividend yield
0.82%
EPS (TTM)
₹59.20
Beta (1Y · daily vs NIFTY 50)
0.30
Beta (5Y · monthly vs NIFTY 50)
0.70
Shares float
14.67 Cr
EPS · quarter ended Sept 2026
₹14.05
Financial Performance
01 · Financials
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based
05 · Capital Structure & Asset Utilization
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
07 · Debt Level & Coverage
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹8,005.00 Cr | ₹8,508.00 Cr | ₹9,620.00 Cr | ₹10,728.00 Cr | ₹11,516.00 Cr | ₹13,980.00 Cr | |
EBITDA | ₹2,542.00 Cr | ₹2,143.00 Cr | ₹2,887.00 Cr | ₹3,500.04 Cr | ₹3,720.00 Cr | ₹4,376.00 Cr |
| ₹1,252.00 Cr | ₹777.00 Cr | ₹1,245.00 Cr | ₹1,656.00 Cr | ₹1,911.00 Cr | ₹2,163.00 Cr | |
Diluted EPS | ₹36.99 | ₹22.97 | ₹36.79 | ₹48.94 | ₹56.47 | ₹63.92 |
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹14,074.65 Cr | ₹13,099.84 Cr | ₹15,011.85 Cr | ₹15,061.00 Cr | ₹14,990.00 Cr | ₹44,312.00 Cr | |
| ₹4,874.13 Cr | ₹4,069.65 Cr | ₹5,368.56 Cr | ₹4,021.94 Cr | ₹3,202.32 Cr | ₹15,025.50 Cr | |
Stockholders' equity | ₹5,837.17 Cr | ₹5,952.95 Cr | ₹6,198.07 Cr | ₹6,856.00 Cr | ₹7,591.00 Cr | ₹8,389.00 Cr |
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹2,011.00 Cr | ₹1,803.00 Cr | ₹2,368.00 Cr | ₹3,266.00 Cr | ₹2,585.00 Cr | ₹3,023.00 Cr | |
Investing cash flow | ₹-449.00 Cr | ₹-198.00 Cr | ₹-2,415.31 Cr | ₹-168.00 Cr | ₹-540.00 Cr | ₹-12,713.00 Cr |
| ₹-1,656.00 Cr | ₹-1,781.00 Cr | ₹77.00 Cr | ₹-2,779.00 Cr | ₹-2,298.00 Cr | ₹10,151.00 Cr | |
Capital expenditure | ₹-335.00 Cr | ₹-203.00 Cr | ₹-574.00 Cr | ₹-433.00 Cr | ₹-611.00 Cr | ₹-677.00 Cr |
End cash position | ₹572.56 Cr | ₹398.40 Cr | ₹508.53 Cr | ₹835.00 Cr | ₹573.00 Cr | ₹1,117.00 Cr |
Debt issued, Debt repaid have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21–Sep 24(14Q) | Dec 24–Jun 26(7Q) | Jul 26 |
|---|---|---|---|
| Promoter | 71.25% | 68.31% | 60.78% |
| Public | 28.75% | 31.69% | 39.22% |
| Employee trusts | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.25 L Cr | ₹1,769.9 | 38.8 | 5.09 | 13.7% | 0.06 | +11.9% | +3.7% |
| Divi's Laboratories Limited | ₹2.66 L Cr | ₹10,037.5 | 90.8 | 15.85 | 15.3% | 0.00 | +12.3% | +47.5% |
| Torrent Pharmaceuticals Limited | ₹1.79 L Cr | ₹4,738.5 | 79.4 | 21.31 | 25.8% | 1.79 | +21.5% | +32.5% |
| Laurus Labs Limited | ₹1.27 L Cr | ₹2,348 | 94.8 | 23.94 | 16.8% | 0.48 | +22.0% | +146.2% |
| Apollo Hospitals Enterprise Limited | ₹1.23 L Cr | ₹8,599.5 | 58.8 | 12.95 | 20.5% | 0.90 | +15.7% | +10.1% |
| Zydus Lifesciences Limited | ₹1.19 L Cr | ₹1,188.1 | 26.7 | 4.40 | 18.6% | 0.46 | +18.4% | +22.3% |
| Lenskart Solutions Limited | ₹1.16 L Cr | ₹689.7 | 181.4 | 13.30 | 5.6% | 0.35 | +35.4% | — |
| Dr. Reddy's Laboratories Limited | ₹1.14 L Cr | ₹1,374 | 40.6 | 3.02 | 11.4% | 0.21 | +3.2% | +14.5% |
| Cipla Limited | ₹1.13 L Cr | ₹1,402 | 38.9 | 3.27 | 11.3% | 0.02 | +2.1% | -6.7% |
| Mankind Pharma Limited | ₹1.03 L Cr | ₹2,475 | 45.9 | 6.31 | 11.7% | 0.39 | +17.0% | +3.1% |
| Aurobindo Pharma Limited | ₹98,101.93 Cr | ₹1,705 | 26.6 | 2.59 | 9.2% | 0.21 | +6.4% | +48.4% |
| Lupin Limited | ₹92,244.53 Cr | ₹2,008.6 | 16.7 | 4.11 | 23.8% | 0.29 | +23.9% | +0.6% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Results: Alembic Pharmaceuticals Limited Beat Earnings Expectations And Analysts Now Have New Forecasts
Simply Wall St · 16 days ago
Emcure Pharmaceuticals Limited Beat Revenue Forecasts By 6.4%: Here's What Analysts Are Forecasting Next
Simply Wall St · 17 days ago